



24 July 2024

To,
The Corporate Relationship Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

The Manager, Listing Department,
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E),
Mumbai - 400 051

Sub: Intimation of a proposed voluntary recall of marketed batches of Allegra Suspension (Fexofenadine Hydrochloride Suspension) and Combiflam Suspension (Ibuprofen and Paracetamol Suspension) (altogether "Products") marketed/distributed by Sanofi Consumer Healthcare India Limited ("Company")

Dear Sir/ Madam,

The Company has submitted applications dated July 8, 2024 and July 5, 2024 with National Stock Exchange of India Limited ("**NSE**") and BSE Limited ("**BSE**"), respectively, for relaxation under sub-rule (7) of rule 19 of Securities Contracts (Regulation) Rules, 1957 ("**SCRR**") and for listing of 23,030,622 equity shares of face value Rs. 10 issued by the Company ("**Listing Application**").

In furtherance of the Listing Application, and as part of our commitment to good corporate governance and reporting standards we would like to inform you that the Company has decided to initiate a voluntary recall of marked batches of Allegra Suspension (Fexofenadine Hydrochloride Suspension) and Combiflam Suspension (Ibuprofen and Paracetamol Suspension), which are manufactured by Mistair Health & Hygiene Private Limited at Plot No3, MIDC, Shirol, Kolhapur, Taluka: Hatkanangale, District-Kolhapur, 416122 ("**Manufacturing Site**") and marketed/distributed by the Company.

This voluntary recall concerns all batches of the Products within shelf-life, at distributors, wholesalers, pharmacies/ retailers and at hospital levels, across Indian markets. While this issue is presently being investigated and all regulatory intimations are being made, out of abundance of caution, all manufacturing and release of the Products at the Manufacturing Site and distributions of the marked batches of the Products from Company distribution centres have been put on hold from June 28, 2024 until a detailed investigation is completed. The Company is taking all necessary steps to resolve the situation. The above voluntary recall is likely to have an impact on the revenue and profitability of the Company.

In furtherance of our Listing Application, the Company submitted a draft Information Memorandum with both NSE and BSE. Accordingly, and in light of the aforementioned material event, we have made the appropriate amendments to the disclosures provided in the Information Memorandum and have shared the updated Information Memorandum separately for your records.

This intimation will also be disclosed on the website of the Company at [Disclosures under Reg. 30 of the Listing Regulations \(sanofi.in\)](#)

Kindly take the same on your record.

Thanking You.

Yours sincerely,

For and on behalf of Sanofi Consumer Healthcare India Limited

Nikunj Savaliya
Company Secretary & Compliance Officer
Membership No: F7048